Michael Andrew Schemick net worth and biography

Michael Schemick Biography and Net Worth

Mr. Schemick joined Certara as Chief Financial Officer in August 2014. He brings 19 years of financial management experience to the company in a wide range of industries, including software and consulting organizations. Before Certara, Schemick served as Vice President of Financial Planning and Analysis for Haights Cross Communications, a holding company for education and media investments, playing a key role in business transformation, strategy, and financial operations on behalf of private equity investors. Schemick also held Chief Financial Officer roles for two divisions of Kaplan Inc, a leading education company, and has significant experience in both public and private equity backed enterprises. Schemick started his career at Arthur Andersen after graduating with an MBA in accounting from Rutgers University. In addition, he has earned the titles of CPA and CTP.

What is Michael Andrew Schemick's net worth?: The estimated net worth of Michael Andrew Schemick is at least $8.58 million as of August 17th, 2022. Mr. Schemick owns 517,870 shares of Certara stock worth more than $8,581,106 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Schemick may own. Learn More about Michael Andrew Schemick's net worth.
How do I contact Michael Andrew Schemick?: The corporate mailing address for Mr. Schemick and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Michael Andrew Schemick's contact information.
Has Michael Andrew Schemick been buying or selling shares of Certara?: Michael Andrew Schemick has not been actively trading shares of Certara within the last three months. Most recently, on Wednesday, August 17th, Michael Andrew Schemick bought 25,000 shares of Certara stock. The stock was acquired at an average cost of $16.64 per share, with a total value of $416,000.00. Following the completion of the transaction, the chief financial officer now directly owns 517,870 shares of the company's stock, valued at $8,617,356.80. Learn More on Michael Andrew Schemick's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

Michael Andrew Schemick Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/17/2022	Buy	25,000	$16.64	$416,000.00	517,870
11/15/2021	Sell	66,666	$37.84	$2,522,641.44
10/18/2021	Sell	66,667	$36.48	$2,432,012.16
9/20/2021	Sell	66,667	$34.62	$2,308,011.54
6/22/2021	Sell	66,666	$26.94	$1,795,982.04	830,177

Michael Andrew Schemick Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $16.57

$16.21

$16.78

50 Day Range

MA: $17.69

$15.93

$19.45

2 Week Range

Now: $16.57

$11.81

$24.64

Volume

321,643 shs

Average Volume

533,272 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>